Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer

Patient-derived tumor organoids are a reliable model for preclinical and translational studies. Despite positive retrospective correlations with patient response data, challenges such as culture success, cost, standardization, and time constraints hinder their clinical utility in guiding precision medicine. This study underscores the utility of patient-derived organoids established from growth factor-reduced media in many facets of precision oncology, showing for the first time in hepatocellular carcinoma, clear benefit to patient survival in a proof-of-concept case study.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-04-22
DOI
https://doi.org/10.1016/j.jhepr.2025.101426
Citations
3
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
4.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer

Hao Huang, Winnie Wing Yan Cheung, Howard H.W. Leung, Xiaofan Ding et al.
3 citations
JHEP Reports
Pharmacogenetics and Drug Metabolism
4.67
article

Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer

Hao Huang, Winnie Wing Yan Cheung, Howard H.W. Leung, Xiaofan Ding, Alissa M. Wong, Stephen L. Chan, Yue Liu, Yin Kau Lam, Kelvin K. Ng, Cecilia Ka Wing Chan, Xin Wang, Luyao Zhang, C. H. Chu, Aikha Melissa Go Wong, Anthony W.H. Chan, Nathalie Wong
article en
3 citations

Abstract

Patient-derived tumor organoids are a reliable model for preclinical and translational studies. Despite positive retrospective correlations with patient response data, challenges such as culture success, cost, standardization, and time constraints hinder their clinical utility in guiding precision medicine. This study underscores the utility of patient-derived organoids established from growth factor-reduced media in many facets of precision oncology, showing for the first time in hepatocellular carcinoma, clear benefit to patient survival in a proof-of-concept case study.

JHEP ReportsVol. 7(7)
Chinese University of Hong Kong (HK), University of Macau (MO), Southeast University (BD), Southeast University (CN)
Openalex Percentile: Top 6%
Pharmacogenetics and Drug Metabolism
4.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer — Hao Huang, Winnie Wing Yan Cheung, et al. · JHEP Reports (2025) | TGRS Research Map | TGRS